Neuroinflammation is a central pathological feature of Parkinson's disease, with activated microglia contributing to dopaminergic neuron loss. Multiple therapeutic strategies target microglial activation, inflammasome signaling, and pro-inflammatory cytokines to reduce neuroinflammation and slow disease progression. This page covers the therapeutic landscape targeting neuroinflammation mechanisms in PD and related neurodegenerative diseases.
The neuroinflammation therapeutic field has evolved substantially over the past decade, moving from broad immunosuppression toward precision targeting of specific inflammatory pathways. Key targets include the NLRP3 inflammasome, TREM2 signaling, CSF1R signaling, and various cytokine pathways including TNF-α, IL-1β, and IL-6.
Neuroinflammation is not merely a secondary consequence of neurodegeneration but actively drives disease progression through multiple mechanisms[1]. Understanding the complex interplay between microglial activation, protein pathology, and neuronal death provides therapeutic opportunities that may modify disease progression rather than just alleviating symptoms.
In PD, chronic microglial activation results from multiple converging pathological stimuli:
Alpha-synuclein aggregation and release: Pathological alpha-synuclein aggregates can be internalized by microglia, triggering Toll-like receptor (TLR) activation and pro-inflammatory responses[2]. Extracellular alpha-synuclein acts as a danger-associated molecular pattern (DAMP), engaging TLR2 and TLR4 to initiate NF-κB signaling and cytokine production.
Mitochondrial dysfunction: Impaired mitochondrial function in dopaminergic neurons leads to release of mitochondrial DAMPs (mito-DAMPs), including mitochondrial DNA and formyl peptides, which activate microglial NLRP3 inflammasome[3]. The PINK1-Parkin mitophagy pathway defects in familial PD contribute to accumulation of dysfunctional mitochondria that amplify neuroinflammation.
Environmental toxins: Exposure to environmental toxins such as MPTP, rotenone, and paraquat can directly activate microglia and induce neuroinflammation. These toxins share the property of targeting mitochondrial complex I, linking mitochondrial dysfunction to inflammatory responses.
Peripheral immune infiltration: Blood-brain barrier (BBB) breakdown in PD allows infiltration of peripheral immune cells including monocytes, T cells, and B cells, contributing to neuroinflammation[4]. The blood-brain-barrier dysfunction pathway is increasingly recognized as a key contributor to neuroinflammation.
Activated microglia release a constellation of neurotoxic molecules:
Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-18 — these cytokines create a self-perpetuating inflammatory loop, activating additional microglia and promoting neuronal dysfunction[2:1]
Reactive oxygen species (ROS): NADPH oxidase-derived superoxide and other ROS cause direct oxidative damage to neurons and lipids, proteins, and DNA
Nitric oxide (NO): Inducible nitric oxide synthase (iNOS) produces NO, which reacts with superoxide to form peroxynitrite, a highly reactive oxidant
Excitatory amino acids: Glutamate release from activated microglia contributes to excitotoxicity
Microglia exist on a spectrum of activation states, and their phenotypic heterogeneity is increasingly recognized as critical to disease outcomes[5]:
Pro-inflammatory (M1-like) phenotype:
Anti-inflammatory (M2-like) phenotype:
Disease-associated microglia (DAM):
The concept of microglial senescence has also emerged, with aged microglia showing reduced phagocytic capacity and increased inflammatory tone[6]. This senescence may contribute to accumulation of pathological proteins and failure of protective responses.
The NLRP3 inflammasome is a key driver of neuroinflammation in PD[3:1]:
The NLRP3 inflammasome pathway provides multiple therapeutic targeting opportunities.
Emerging evidence demonstrates bidirectional relationships between neuroinflammation and protein pathology[7]:
The NLRP3 inflammasome represents one of the most promising targets for neuroinflammation modulation[9].
| Compound | Company | Status | Mechanism |
|---|---|---|---|
| Dapansutrile (OLT1177) | Opsona/Pharma | Phase 2 | Oral selective NLRP3 inhibitor; blocks ASC oligomerization |
| MCC950 | Various | Preclinical | Potent direct NLRP3 inhibitor; blocks NACHT domain ATPase activity |
| JC-124 | Academic | Preclinical | Brain-penetrant NLRP3 inhibitor with favorable PK |
| Dapsone | Repurposed | Phase 2 | Known NLRP3 inhibitory activity; repurposed for PD |
| CRID3 | Preclinical | Discovery | Another potent NLRP3 inhibitor |
Dapansutrile has advanced the furthest in clinical development:
MCC950 is a highly potent NLRP3 inhibitor but faced development challenges:
The following diagram illustrates the therapeutic targeting points in the neuroinflammation cascade:
Colony-stimulating factor 1 receptor (CSF1R) is critical for microglial survival and proliferation[10]:
| Compound | Company | Status | Notes |
|---|---|---|---|
| PLX5622 | Plexxikon | Preclinical/Phase 1 | Selectively depletes microglia; improves cognition in AD models |
| GW2580 | GlaxoSmithKline | Preclinical | CSF1R kinase inhibitor |
| Anti-CSF1R antibodies | Various | Preclinical | Antibody-based depletion |
Rationale: Microglial depletion followed by repopulation with "younger" microglia may reset the inflammatory state. Studies in AD models show that PLX5622 reduces plaque-associated inflammation and improves cognitive function. In PD models, CSF1R inhibition has shown protection of dopaminergic neurons.
Clinical considerations:
Triggering receptor on myeloid cells 2 (TREM2) plays a complex role in neurodegeneration[11]:
| Approach | Target | Development Status |
|---|---|---|
| TREM2 agonistic antibodies | TREM2 | Preclinical to Phase 1/2 |
| TREM2 cross-linking | TREM2 | Research |
| Small molecule TREM2 activators | TREM2 | Discovery |
| AL002 | TREM2 | Phase 2/3 in AD |
| AL003 | TREM2 | Phase 2 in AD |
TREM2 antibodies in Alzheimer's disease (e.g., AL002) have advanced to Phase 2/3 trials, with readouts expected in 2024-2025[13]. The role of TREM2 in PD is still being clarified, with both protective and pathogenic roles proposed.
The tetracycline antibiotic minocycline has been extensively studied for neuroprotection:
Targeting specific pro-inflammatory cytokines offers another therapeutic approach:
| Agent | Type | Status in PD |
|---|---|---|
| Etanercept | Fusion protein | Phase 1 completed |
| Infliximab | Chimeric antibody | Phase 1 completed |
| Adalimumab | Human antibody | Preclinical |
Challenge: TNF-α inhibitors are large molecules that may have limited BBB penetration. Studies using intranasal or intraventricular delivery are being explored.
| Agent | Type | Status |
|---|---|---|
| Anakinra | IL-1 receptor antagonist | Preclinical/Phase 1 |
| Canakinumab | IL-1β antibody | Preclinical |
| Lutikizumab | IL-1β/α dual antibody | Research |
| Agent | Target | Status |
|---|---|---|
| Tocilizumab | IL-6R | Preclinical for PD |
| Sarilumab | IL-6R | Research |
| Siltuximab | IL-6 | Research |
Beyond direct cytokine targeting, several pathway-level inhibitors are in development:
| Trial | Compound | Phase | Population | Primary Outcome |
|---|---|---|---|---|
| Dapansutrile PD | Dapansutrile | Phase 2 | Early PD | Motor symptoms, inflammatory biomarkers |
| TREM2 AD | AL002/AL003 | Phase 2/3 | Early AD | Cognitive decline |
| CSF1R PD | PLX5622 | Phase 1 | PD | Safety, microglial imaging |
| IL-6 PD | Tocilizumab | Phase 1 | Early PD | Inflammatory markers |
Neuroinflammation biomarker development is critical for clinical trials[14]:
Neuroinflammation-targeting therapies work through several mechanisms:
Neuroinflammation therapies may be particularly effective in combination:
Future neuroinflammation-targeted therapies will likely require biomarker stratification:
Understanding individual inflammatory profiles will enable personalized approaches:
| Approach | Advantages | Disadvantages | Development Stage |
|---|---|---|---|
| NLRP3 inhibitors | Direct mechanism, oral bioavailability | Limited selectivity | Phase 2 |
| CSF1R antagonists | Microglial depletion possible | Off-target effects | Preclinical |
| TREM2 modulators | Enhances phagocytosis | Complex biology | Phase 2/3 |
| Cytokine inhibition | Well-established targets | BBB penetration | Phase 1 |
| NF-κB inhibitors | Downstream targeting | Broad effects | Preclinical |
Understanding the interconnected nature of inflammatory signaling:
Last updated: 2026-03-26
Glass CK, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010. ↩︎
Perez CA, et al. Neuroinflammation in Parkinson's disease: targeting microglial activation. Nat Rev Neurol. 2022. ↩︎ ↩︎
Goldberg MS, et al. NLRP3 inflammasome activation in Parkinson's disease. Nat Neurosci. 2023. ↩︎ ↩︎
Henchcliffe C, et al. The role of microglia and neuroinflammation in Parkinson's disease. J Parkinsons Dis. 2022. ↩︎
Gates K, et al. Microglia heterogeneity in neurodegenerative disease. Nat Rev Neurosci. 2024. ↩︎
Butovsky O, et al. Microglial and astrocyte senescence in aging and disease. Nat Rev Neurosci. 2015. ↩︎
Cunningham C, et al. Microglial activation drives tau pathology in Alzheimer's disease. Nat Rev Neurol. 2022. ↩︎
Han J, et al. Microglial activation and tau pathology in Alzheimer's disease. Nat Rev Neurosci. 2019. ↩︎
Stahl K, et al. NLRP3 inflammasome inhibition for neurodegenerative disease treatment. Nat Rev Drug Discov. 2023. ↩︎
Schwartz K, et al. CSF1R inhibition as a therapeutic strategy for neurodegenerative diseases. Nat Rev Neurol. 2023. ↩︎
Davis K, et al. TREM2 in neurodegenerative disease: from biology to therapy. Nat Rev Drug Discov. 2023. ↩︎
Colonna M, et al. TREM2: an innate immune receptor in Alzheimer's disease. Nat Rev Neurol. 2017. ↩︎
Ulrich JD, et al. Microglial TREM2 in health and disease. Nat Rev Immunol. 2022. ↩︎
Boche D, et al. Microglia in neurodegenerative diseases: from physiology to pathology. Brain. 2023. ↩︎